A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Autor: Stavros Chrysidis, B. Glintborg, Niels Steen Krogh, Lis Smedegaard Andersen, Jimmi Sloth Olsen, Dorte Vendelbo Jensen, Jolanta Grydehøj, Michael Veedfald Sørensen, Salome Kristensen, Natalia Manilo, Merete Lund Hetland, Mette Klarlund, Oliver Hendricks, Inge Juul Sørensen, Sabine Sparre Dieperink, Asta Linauskas, Inger Marie Jensen Hansen, Henrik Nordin, Jakob Espesen, Kathrine Lederballe Grøn, Dorte Dalsgaard Pedersen, Lars Pedersen, Hanne Merete Lindegaard, Anne Gitte Loft

Publikováno v: Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L & Hetland, M L 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L, Hetland, M L & all departments of rheumatology in Denmark 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742

ObjectivesAccording to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8575d080f35c2e1d089ff61ce2e62eb4
https://doi.org/10.1136/annrheumdis-2016-210742